Santhera Pharmaceuticals

We had an incredible experience on October 17 & 18, presenting at the University of St.Gallen MBA program on the exciting careers in #LifeSciences. Our team at Santhera Pharmaceuticals shared insights on the pharmaceutical world, drug development, and how #Onboarding, #Hiring, #DEI and #LeadingThroughChange are critical for building a diverse and innovative workforce.   It was an honor to engage with these brilliant students and faculty, exchanging ideas and discussing the future of pharma and scientific discovery. A big thank you to Jost Gloor for inviting us to participate, and to everyone who joined us -we’re excited for future collaborations!

Santhera will host a booth at the WMS Congress (8th -12th October | Prague, Czechia) exclusively for healthcare professionals (HCPs).

We are happy to announce that Swissmedic has accepted for review Santhera's marketing authorization application for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD)! -- “Submission of AGAMREE for DMD to Swissmedic is an important milestone, following approvals from the U.S. FDA, the European Commission in the EU, and the UK MHRA, in addition to acceptance for priority review from China’s NMPA,” commented Shabir Hasham, MD, Chief Medical Officer of Santhera. “We look forward to working closely with Swissmedic to address the high unmet need for improved treatment options for patients suffering from DMD in Switzerland.” Read our full press release here: https://bit.ly/3XT8U6x #Santhera #duchenne #DMD #msculardystrophy #theirfutureourfocus

The Investora Zurich conference brings together the leadership of listed Swiss companies and small to mid-cap investors. Santhera’s CFO Andrew Smith will be presenting the Company and its perspectives today, September 19 at 16:20h, and we look forward to connecting with you there! #santhera #theirfutureourfocus

Today, we published H1-2024 results and provided an update on our performance, exceeding expectations! Santhera's CEO Dario Eklund, CFO Andrew Smith and CMO Shabir Hasham, MD, summarized half-year events and discussed recent highlights and prospects. -- You missed it? We invite you to access the replay at https://bit.ly/3XzJs6n #Santhera #theirfutureourfocus"

We are pleased to have entered into an exclusive distribution agreement with GENESIS Pharma for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in 20 markets in Central and Eastern Europe. “This marks a significant achievement for Santhera as we expand the global availability of AGAMREE. By partnering with expert organizations with a strong understanding of specialist markets, we ensure optimal patient access,” said Geert Jan van Daal, MD, PhD, Chief Commercial Officer of Santhera. “This is a further step in our strategy to allow focus on key European markets with dedicated Santhera teams while partnering with the best companies for non-core European markets.” Read the full press release here https://bit.ly/3B9P1PC #santhera #theirfutureourfocus #DMD #Duchenne

This weekend marks #WorldDuchenneAwarenessDay, a remarkable opportunity to celebrate the incredible stories of patients and caregivers living with Duchenne muscular dystrophy (DMD). It also provides a moment to recognize the dedication of those working tirelessly behind the scenes. At Santhera, we are committed to the DMD community.💙   Through our internal #StepsForStrength campaign, our employees have collectively taken millions of steps to raise funds for the @WorldDuchenneOrganization's Emergency Program coordinated by @NicolettaMadia. Working together and living our values to make a difference for patients, every step we take in this campaign is not just a number but a demonstration of the strength of our collective spirit. In our own small way, we can make a difference and #RaiseOurVoiceforDuchenne. 💙🎈 #DuchenneMuscularDystrophy #DMD #DMDstories #WDO #WorldDuchenneOrganization #StepsForStrength #S4S #StrongerTogether #WorldDuchenneAwarenessDay #DMDAwarenessDay #raiseyourvoiceforDuchenne #WDAD2024

This weekend marks #WorldDuchenneAwarenessDay, a remarkable opportunity to celebrate the incredible stories of patients and caregivers living with Duchenne muscular dystrophy (DMD). It also provides a moment to recognize the dedication of those working tirelessly behind the scenes. At Santhera, we are committed to the DMD community.💙   Through our internal #StepsForStrength campaign, our employees have collectively taken millions of steps to raise funds for the @WorldDuchenneOrganization's Emergency Program coordinated by @NicolettaMadia. Working together and living our values to make a difference for patients, every step we take in this campaign is not just a number but a demonstration of the strength of our collective spirit. In our own small way, we can make a difference and #RaiseOurVoiceforDuchenne. 💙🎈 #DuchenneMuscularDystrophy #DMD #DMDstories #WDO #WorldDuchenneOrganization #StepsForStrength #S4S #StrongerTogether #WorldDuchenneAwarenessDay #DMDAwarenessDay #raiseyourvoiceforDuchenne #WDAD2024

When it comes to diagnosing Duchenne muscular dystrophy (DMD) every day counts. That’s because earlier diagnosis also means: 🔜 Earlier access to support networks 🔜 Earlier access to management options 🔜 Earlier opportunities to start treatment — vital to slowing disease progression   If you have any concerns about your child’s development, your pediatrician will be able to offer the advice you need.   #DuchenneMuscularDystrophy #Santhera #TheirFutureOurFocus #DMD

Strength is also about resilience in the face of adversity. To all those battling DMD, your courage and unwavering spirit are a beacon of hope for the community and for us at Santhera. Keep fighting, keep believing, because every day you inspire us to do more.💙 #DuchenneMuscularDystrophy #DMDWarriors #CourageousHearts #Santhera #TheirFutureOurFocus #DMD